Bladder cancer trials in China

In China 167 Also abroad 630

134 of 167 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Where
Shanghai
Age
18 years to 80 years
People
740
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06879145
Phase 2Taking people
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Where
Beijing, Chengdu, Langfang, Shanghai
Age
18 years and over
People
240 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806
Phase 1Taking people
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Where
Shenzhen
Age
18 years to 75 years
People
42
Run by
Beijing Biotech
See details and how to joinNCT07492628
Phase 3Taking people
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Where
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Jiaxing, Nanchang, Nanjing, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Zhuhai
Age
18 years and over
People
590 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07419295 · EU 2024-520014-22-00
Phase 1Not yet taking people in China
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Where
Changsha
Age
18 years and over
People
540 worldwide
Run by
Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00
Phase 1Not yet taking people in China
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
Where
Guangzhou
Age
18 years and over
People
20
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07853053
Phase 1Taking people
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Where
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi’an
Age
18 years and over
People
677 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Beijing, Guangzhou, Shanghai
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Beijing, Changsha, Hangzhou, Shanghai
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Active, not recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai, Tianjin, Ürümqi, Wenzhou, Wuhan, Xinshi, Xuzhou
Age
18 years and over
People
641 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06319820
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Where
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan, Yantai
Age
18 years and over
People
220 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00
No phaseTaking people
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Where
Guangzhou, Kunming, Nanchang, Shanghai, Tianjin, Xingtai
Age
18 years and over
People
350
Run by
Tianjin Medical University Second Hospital
See details and how to joinNCT07187635
Phase 2Taking people
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Where
Taiyuan
Age
18 years and over
People
50
Run by
Shanxi Province Cancer Hospital
See details and how to joinNCT07646145
Phase 2Not yet taking people in China
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
Where
Beijing
Age
18 years and over
People
20
Run by
Peking University First Hospital
See details and how to joinNCT07720921
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Chengdu, Guangzhou
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 2Not yet taking people in China
Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Where
Tianjin, Xingtai
Age
18 years and over
People
150
Run by
Tianjin Medical University Second Hospital
See details and how to joinNCT07879469
Phase 2Taking people
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Where
Tianjin, Xingtai
Age
18 years and over
People
120
Run by
Tianjin Medical University Second Hospital
See details and how to joinNCT07625527
No phaseTaking people
18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
Where
Beijing
Age
18 years and over
People
80
Run by
Peking University First Hospital
See details and how to joinNCT07875959
No phaseTaking people
Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
Where
Guangzhou
Age
18 years to 100 years
People
96
Run by
Zhujiang Hospital
See details and how to joinNCT03108196
Phase 2Taking people
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
Where
Guangzhou
Age
18 years to 75 years
People
41
Run by
Zhujiang Hospital
See details and how to joinNCT04861584
No phaseTaking people
Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men With Bladder Cancer
Where
Guangzhou
Age
20 years and over
People
126
Run by
Zhujiang Hospital
See details and how to joinNCT05067101
No phaseTaking people
Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
Where
Daqing, Nanchang, Tianjin
Age
18 years and over
People
670
Run by
Tianjin Medical University Second Hospital
See details and how to joinNCT07749924
Phase 1/2Taking people
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Where
Guangzhou
Age
18 years and over
People
55
Run by
Zhujiang Hospital
See details and how to joinNCT06341400
Phase 1/2Taking people
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Where
Beijing, Nanjing, Ningbo, Tianjin
Age
18 years and over
People
132 worldwide
Run by
Pfizer
See details and how to joinNCT07421700 · EU 2025-523523-21-00
Phase 2Not yet taking people in China
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
Where
Wuhan
Age
18 years and over
People
70
Run by
Tongji Hospital
See details and how to joinNCT07865611